最新ニュース Valneva (NASDAQ:VALN) 株価情報

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE

Since last quarter and through today, the Company has executed 650,000 square feet of leasing activity throughout its portfolio, underscoring the strength of Brandywine's core portfolio while demonstrating continued progress executing leases within its development pipeline. The fourth quarter leasing activity was the highest in 2024 and 18% higher than the fourth quarter of 2023. The weighted average lease term for the quarter was 9.4 years with total leasing activity for 2024 at 2.2 million square feet.

News

Reported Earlier, Brandywine Realty Trust Reports Strong Leasing Momentum With 650,000 Square Feet Leased In Q4 2024

SPHR

Reported Earlier, MSG Networks Seeks Neutral Arbitration To Restore Knicks, Rangers, Devils, And Islanders Coverage For Optimum Subscribers

HSDT

Reported Earlier, Helius Medical Technologies Executes Warrant Exercise Agreements For $3.7M Gross Proceeds, Introduces New Warrants

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 375,000 shares of common stock at the initial public offering price, representing 15% of the Shares sold in the Offering, less underwriting discounts and commissions, to cover over-allotments. The Offering is expected to close on or about January 23, 2025, subject to satisfaction of customary closing conditions.
The Company's common stock is expected to begin trading on the NYSE American on January 22, 2025, under the symbol "TOPP."&nbsp;

IPOs

TOPP

Reported Earlier, Toppoint Prices $10M Initial Public Offering Of 2.5M Common Shares At $4/Share

Production
<ul>
<li>Woodside's full-year 2025 production guidance is 186 – 196 MMboe (510 – 537 Mboe/day). This excludes volumes from Beaumont New Ammonia.</li>
<li>The approximate split by product type is:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">LNG</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~40%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pipeline gas</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~20%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Crude and condensate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~35%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Natural gas liquids</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~5%</td>
</tr>
</tbody>
</table>
</figure>

Earnings

Guidance

Woodside Provides 2025 Guidance: Sees 186–196 MMboe Production And $4.5B–5B Capex Allocation

Operations
<ul>
<li>Outstanding production from Sangomar with 75 Mboe/day produced in the quarter, driving record full-year production of 194 MMboe (530 Mboe/day), at the top end of the 2024 full-year production guidance range.</li>
<li>Quarterly production of 51.4 MMboe. (559 Mboe/day), down 3% from Q3 2024 due to lower seasonal demand at Bass Strait and an unplanned shutdown at Pluto, partly offset by increased production at Sangomar.</li>
<li>Quarterly revenue of $3,470 million, down 6% from Q3 2024 primarily due to lower seasonal demand at Bass Strait, partly offset by higher third-party LNG trades.</li>
<li>Sold 33.6% of produced LNG at prices linked to gas hub indices in the quarter (12.8% of total equity production), realising a 31% premium compared to oil-linked pricing.</li>
</ul>
Projects
<ul>
<li>The Scarborough Energy project was 78% complete at the end of the quarter, with the final Pluto Train 2 modules arriving at the Pluto LNG site in December. The project remains on target for first LNG cargo in 2026.</li>
<li>The Trion project was 20% complete at the end of the quarter, with construction of the floating production unit commencing in November. First oil is targeted for 2028.</li>
<li>Continued construction of the Beaumont New Ammonia project with Phase 1 of the project on track for start up in the second half of 2025.</li>
</ul>

Reported Earlier, Woodside Energy Q4 Revenue $3.47B Up From $3.355B YoY

Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea
Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:<a href="https://www.benzinga.com/stock/EVTd#TRQX">EVTd</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

Government

Evotec Partners with Yonsei University and Zymedi to Develop Lung Disease Therapies with $4.5M Grant

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) to report quarterly earnings at $1.34 per share on revenue of $11.01 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Abbott shares went up 0.08% to $116.88 in after-hours trading.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected fourth-quarter financial results. Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year. The company said it sees full-year revenue of $43.5 billion to $44.5 billion, up $0.5 billion from the company&#8217;s previous range. Netflix shares jumped 14.4% to $994.80 in the after-hours trading session.</li>
<li>Analysts are expecting Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.86 per share on revenue of $21.54 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 1% to $163.38 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) posted better-than-expected fourth-quarter financial results. The company reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.84 per share. The company reported quarterly sales of $1.39 billion which beat the analyst consensus estimate of $1.37 billion. Interactive Brokers shares gained 3.5% to $199.59 in the after-hours trading session.</li>
<li>Analysts expect Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) to post quarterly earnings at $2.01 per share on revenue of $22.44 billion before the opening bell. Johnson &amp; Johnson shares gained 0.6% to $149.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

IBKR

NFLX

Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday

The alliance combines the deep technical expertise of McKinsey's AI practice, QuantumBlack, and its track record of deploying and scaling AI solutions across industries with C3 AI's cutting-edge Enterprise AI software applications to help clients unlock the power of Enterprise AI and agentic AI to realize significant operational improvements and unlock new growth opportunities.

C3 AI And McKinsey Announce Alliance To Drive Rapid And Scalable AI Solutions For Global Enterprises

Announces intent to spin out and form a growth-oriented joint venture for LanzaX, the Company's&nbsp;differentiated synthetic biology platform, with Tharsis Capital joining as new LanzaX strategic partner to accelerate financing for the synbio development pipeline
Appoints new Interim Chief Financial Officer of LanzaTech to streamline biorefining platform growth priorities and heighten focus on cost reductions

LNZA

Reported Earlier, LanzaTech To Spin Out LanzaX Synbio Division In Joint Venture With Tharsis Capital; Appoints Justin Pugh As Interim CFO

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as major tech companies increasingly invest in AI-powered healthcare solutions.
What Happened: Isomorphic Labs, an Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary, is targeting major disease areas including oncology, cardiovascular conditions, and neurodegeneration, founder Demis Hassabis <a href="https://www.ft.com/content/41b51d07-0754-4ffd-a8f9-737e1b1f0c2e">told</a> Financial Times, speaking at the World Economic Forum in Davos. 
The company has already secured partnerships with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) for six drug development programs.
&#8220;It usually takes an average of five to 10 years to discover one drug. And maybe we could accelerate that 10 times, which would be an incredible revolution in human health,&#8221; said Hassabis, who recently received the Nobel Prize in Chemistry.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a>
Why It Matters: The announcement comes as Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) unveiled plans for an AI-driven cancer vaccine system capable of delivering personalized treatments within 48 hours. The initiative is <a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment">part of a $500 billion AI infrastructure project</a> called Stargate, developed in partnership with OpenAI and SoftBank Group.
Investment in AI-powered drug discovery has gained momentum, with ARK Invest CEO Cathie Wood projecting a $400 billion market opportunity in <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">biologics over the next five years</a>. The sector has attracted significant attention from investors, though companies like Crispr Therapeutics AG and Intellia Therapeutics Inc. have shown considerable market volatility.
Isomorphic Labs, spun out from Google DeepMind in 2021, represents a growing trend of tech giants leveraging AI to streamline the traditionally lengthy and expensive drug development process. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119243/martin-shkreli-calls-ionq-and-rigetti-best-shorts-despite-recent-stock-gains-cites-offline-quantum-systems">Martin Shkreli Calls IonQ And Rigetti &#8216;Best Shorts&#8217; Despite Recent Stock Gains, Cites Offline Quantum Systems</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Biotech

Equities

Health Care

Tech

CRSP

GOOGL

NTLA

ORCL

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

Elon Musk&#8217;s rocket manufacturing company <a href="https://www.benzinga.com/general/space/25/01/42755343/spacex-hits-new-milestone-in-2024-with-134-launches">SpaceX</a> on Tuesday launched its Falcon 9 rocket with 27 Starlink satellites to low-Earth orbit from California and subsequently landed a Falcon 9 rocket booster for the 400th time.
What Happened: Following separation from the rocket&#8217;s second stage, the booster that supported the Starlink mission landed back on Earth, enabling the company to reuse it for another mission.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Falcon lands for the 400th time! <a href="https://t.co/pwNCwAb3SK">pic.twitter.com/pwNCwAb3SK</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1881732223831080967?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The booster that supported the mission on Tuesday previously launched Oneweb 4, USSF-62, and other Starlink missions. The maximum number of missions to be flown by one Falcon 9 booster to date is 25.
Why It Matters: SpaceX is attempting to make its rockets reusable to bring down the cost of spaceflight as the cost of the first stage constitutes the majority of the cost of a new rocket. 
In July 2023, Musk warned that rocket manufacturers will&nbsp;<a href="https://www.benzinga.com/news/23/07/33383081/elon-musk-tells-rocket-makers-go-all-in-on-reusability-or-be-utterly-uncompetitive" target="_blank" rel="noreferrer noopener">need to go all-in on reusability</a>&nbsp;or risk being uncompetitive.
&#8220;Rockets are no different from other transport technologies, just harder to make reusable. No one would buy a single-use airplane, car, or even bicycle! You&#8217;d need to tow another car just for the return trip,&#8221; Musk said.
While the Falcon 9 is only partially reusable, SpaceX is attempting to make its Starship launch vehicle wholly reusable, landing back not just the booster but also the spacecraft. However, the Starship is currently only in the <a href="https://www.benzinga.com/25/01/43052113/bezos-musk-extend-cordial-support-despite-building-rivalry-between-their-rocket-companies">testing and development phase. </a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

SpaceX Falcon 9 Delivers 27 Starlink Satellites To Orbit, Marks 400th Booster Landing

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/JNJ/earnings">opening bell on Wednesday, Jan. 22, 2025.</a>
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.02 per share, down from $2.29 per share in the year-ago period. Johnson &amp; Johnson projects to report revenue of $22.45 billion for the recent quarter, compared to $21.39 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Johnson &amp; Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressants. Previously, it was only approved with oral antidepressants for treatment-resistant depression.
Johnson &amp; Johnson shares gained 0.8% to close at $148.15 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/jnj/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>B of A Securities analyst Tim Anderson maintained a Neutral rating and cut the price target from $166 to $160 on Jan. 17, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and cut the price target from $185 to $175 on Dec. 11, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Guggenheim analyst Vamil Diwan maintained a Neutral rating and raised the price target from $156 to $162 on Nov. 6, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and raised the price target from $163 to $166 on Oct. 16, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $169 to $175 on Oct. 16, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-1024x572.png" alt="" class="wp-image-743946" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22013350/image-136.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Price Target

Analyst Ratings

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

"Since our initial investment in 2021, we have observed the acceleration of Form Technologies' commercial success through its differentiated solutions-based offering and engineering excellence," said Aaron Rosen, Partner and Co-Head of Opportunistic Credit at Ares Management. "We believe that under David's leadership, Form Technologies is well-positioned to address the growing needs of its diversified customer base across key regions and sectors. We look forward to the exciting opportunities ahead as we support the team's goals for driving revenue growth and value creation."

ARES

Reported Earlier, Ares Management Becomes Majority Shareholder In Form Technologies With $304M Investment To Drive Long-Term Growth

New agentic and generative AI capabilities in Oracle Fusion Cloud Sales help enhance customer engagements and accelerate sales processes

Reported Earlier, Oracle Introduces Generative AI And Intelligent Agents To Revolutionize Sales Team Productivity And Customer Connections

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shareholders on Tuesday approved a proposal to increase the company&#8217;s authorized Class A shares by 30 times to support future Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisitions.
What happened: About 56% of votes were cast in favor of increasing the shares from the current 330 million to 10.33 billion, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-21/microstrategy-share-increase-approved-to-fund-bitcoin-purchases">reported</a>, citing the meeting's recording.&nbsp;
Investors also approved the proposal to increase the number of authorized shares of preferred stock from 5 million to 1.005 billion, reflecting a 201x increase. <a href="https://www.benzinga.com/money/how-to-buy-preferred-stock#:~:text=Preferred%20stocks%20usually%20offer%20fixed%20dividends%20and%20rank%20higher%20than,health%20of%20the%20issuing%20company.">Preferred stocks</a> usually offer fixed dividends and rank higher than common stocks during asset liquidation.
Notably, the proposals were <a href="https://www.benzinga.com/24/12/42665877/microstrategy-to-hold-special-shareholder-vote-to-support-the-42-billion-bitcoin-acquisition-strategy">put forward</a> by the firm&#8217;s co-founder and executive chairman, Michael Saylor, who controls 47% of the voting power.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/01/43087038/trump-names-uyeda-acting-sec-chair-as-crypto-regulations-get-set-for-a-makeover">Trump Names Uyeda Acting SEC Chair, Regulators Get Ready For Crypto Makeover</a>
Why It Matters: These proposals were intended to support MicroStarategy's ambitious <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">21/21 plan</a>, a capital-raising operation that seeks to generate $21 billion in equity financing and $21 billion in fixed-income securities to fund Bitcoin purchases.
As of this writing, the firm has $5.42 billion remaining under its equity offerings plan.
MicroStrategy has front-run corporate Bitcoin adoption, with the company&#8217;s stockpile growing to 461,000 BTC, worth $48.67 billion, after a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43104549/microstrategy-buys-11000-bitcoin-total-holdings-reach-461000-btc">fresh purchase</a> of 11,000 BTC on Tuesday. The firm was sitting on unrealized Bitcoin gains of nearly 66%, <a href="https://bitcointreasuries.net/">according </a>to BitcoinTresuries.net.
Price Action: At the time of writing, Bitcoin was exchanging hands at $105,605.91, up 4.04% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Shares of MicroStrategy closed 1.87% lower at $389.10 during Tuesday's regular trading session.
The stock has a <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">consensus price target</a> of $449.5 based on 12 analyst ratings, with an average price target of $546.67 from Bernstein, TD Cowen, and Barclays.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43086309/trumps-doge-committee-faces-lawsuit-over-alleged-federal-advisory-violations-and-lack-of-transparency">Trump&#8217;s DOGE Committee Faces Lawsuits Over Alleged Federal Advisory Violations, Lack Of Transparency</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Michael Saylor's Proposal To Increase MicroStratagy's Share Count Approved By Shareholders — More Bitcoin Purchases On The Cards?

Reported Earlier, EHang Launches Urban Air Mobility Center In Luohu District With First Automated eVTOL Vertiport

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
<ul>
<li>Approval is based on positive results from the IMROZ phase 3 study, demonstrating Sarclisa in combination with standard-of-care treatment significantly improved PFS, compared to the standard of care alone in TI NDMM</li>
<li>Represents third indication in the EU, including two for the treatment of adult patients with R/R MM, and one in NDMM</li>
</ul>

EU Approves Sarclisa In Combination With VRd As A Treatment For Transplant-Ineligible Adults With Newly Diagnosed Multiple Myeloma

LG Display Co Q4 Sales $5.61B Miss $5.87B Estimate, Net Loss $600.7M Down From Net Income $36.2M YoY

Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) announced a 16% price increase for its standard streaming plan on Tuesday, prompting economist Peter Schiff to warn of persistent inflation risks ahead of potential policy shifts under President Donald Trump&#8216;s administration.
What Happened: The streaming giant raised its ad-free standard plan from $15.49 to $17.99 monthly while increasing its premium tier to $24.99 and the ad-supported option to $7.99. 
The price hikes coincided with Netflix&#8217;s robust <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">fourth-quarter earnings report</a>, which showed revenue climbing 16% year-over-year to $10.25 billion and subscriber growth of 18.91 million, bringing total paid memberships to 301.63 million.
Schiff, a vocal critic of current monetary policy, cautioned on X that the Netflix price increase signals broader inflationary pressures. &#8220;The lull in the inflation storm is over. The consequences of inflationary monetary policy that finally showed up under Biden will kick into a higher gear under Trump,&#8221; he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today, Netflix announced a 16% price increase. Those expecting lower inflation under Trump will be disappointed. The lull in the inflation storm is over. The consequences of inflationary monetary policy that finally showed up under Biden will kick into a higher gear under Trump.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1881915137327845422?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment">Oracle&#8217;s Larry Ellison Says Cancer Vaccine Tailored In 48 Hours Could Soon Be A Reality As Trump Announces $500 Billion AI Investment</a>
Why It Matters: The economist&#8217;s warning comes amid broader market discussions about potential economic policies under a Trump presidency. A survey in October found 68% of economists <a href="https://www.benzinga.com/news/24/10/41312782/trumps-economic-policies-expected-to-drive-inflation-and-deficits-higher-than-harris-economists-say">expecting higher inflation under</a> Trump compared to alternative policies, with particular attention to proposed tax cuts without corresponding spending reductions.
Netflix&#8217;s strong performance, including record operating income exceeding $10 billion for fiscal 2024, suggests continued growth potential. The company projects 2025 revenue between $43.5 billion and $44.5 billion, representing 12-14% growth while emphasizing its small current share of the estimated $650 billion market <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">opportunity across its key regions</a>.
Price Action: NFLX shares surged 14.39% to $994.89 in after-hours trading, setting new 52-week highs following the earnings announcement, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43118598/warren-buffetts-pilot-co-exits-global-oil-trading-refocuses-on-us-operations-report">Warren Buffett&#8217;s Pilot Co Exits Global Oil Trading, Refocuses On US Operations: Report</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

Valneva

ニュース

最新ニュース Valneva (NASDAQ:VALN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル